How does zilucoplan actually stop muscle weakness in myasthenia gravis?
Zilucoplan blocks complement protein C5, a key immune molecule that attacks and damages the junction where your nerves connect to muscles. By stopping this attack, your muscles regain strength—67% of patients in the FDA trial showed meaningful improvement within 24 weeks [1].
In myasthenia gravis, your immune system mistakenly makes antibodies that attack the acetylcholine receptors at the neuromuscular junction—the tiny space where nerve signals tell muscles to contract. Complement proteins (especially C5) amplify this attack, causing inflammation and muscle damage. The RAISE Phase 3 trial showed 67% of zilucoplan patients achieved a ≥3-point improvement on the Myasthenia Gravis Composite Score versus only 29% on placebo [1].
Zilucoplan works by binding to C5 and preventing it from splitting into active fragments that fuel inflammation. Think of it as putting a lock on the accelerator of your immune attack. Once C5 is blocked, the inflammatory cascade stops, and your existing muscle fibers can heal and function better without constant immune bombardment [4].
The real-world payoff: 41% of zilucoplan patients were able to cut their corticosteroid dose in half or more, reducing long-term steroid side effects like bone loss and infections [3]. However, you still need baseline kidney function (eGFR ≥30) and regular blood work every 12 weeks to catch any rare immune complications early [9].
Ask your neurologist: 'Do I need a baseline complement level test before starting, and how often will we check my kidney function?' This simple question ensures you're monitored safely and can catch any rare complications before they become serious.